Studies of Wegovy in higher-than-approved doses begin
In January, Novo Nordisk initiated two late-stage studies of semaglutide, the substance in both obesity drug Wegovy and diabetes drug Ozempic, in higher doses than currently approved.
.jpg)
by marketwire, translated by daniel pedersen
This month, Novo Nordisk initiated two phase III trials of Wegovy (semaglutide), testing higher doses than the currently approved 2.4mg, revealed the Danish drugmaker’s annual report for 2022 on Wednesday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk doubles obesity sales in 2022
For subscribers
Novo Nordisk predicts wide range for 2023 sales growth
For subscribers
.jpg&w=384&q=75)
